PET/CT in primary musculoskeletal tumours: a step forward.
Hybrid imaging with combined positron emission tomography/computed tomography (PET/CT) plays an important role in the staging and management of a wide variety of solid tumours. However, its use in the evaluation of musculoskeletal malignancy has not yet entered routine clinical practice. Cross-sectional imaging with magnetic resonance imaging (MR) and computed tomography have well-established roles but there is increasing evidence for the selective use of PET/CT in the management of these patients. The aims of this article are to review the current evidence and clinical applications of PET/CT in primary musculoskeletal tumours and discuss potential future developments using novel PET tracers and integrated PET/MR.
Lakkaraju
A
A
Departments of Radiology and Nuclear Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Patel
C N
CN
Bradley
K M
KM
Scarsbrook
A F
AF
D001859:Bone Neoplasms / Q000175:diagnosis*; D019788:Fluorodeoxyglucose F18; D005544:Forecasting; D006801:Humans; D019042:Muscle Neoplasms / Q000175:diagnosis*; D049268:Positron-Emission Tomography / Q000639:trends*; D019275:Radiopharmaceuticals; D013382:Subtraction Technique / Q000639:trends*; D014057:Tomography, X-Ray Computed / Q000639:trends*
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18